Premium
Age macular degeneration: clinical, biological, morphologic, structural biomarkers for atrophy complication
Author(s) -
Gonzalez C.
Publication year - 2016
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2016.0318
Subject(s) - atrophy , medicine , complication , ophthalmology , macular degeneration , pathology , fundus (uterus)
Purpose To determine clinical, biological, morphologic, structural elements as biomarkers for AMD Atrophy complication Methods AMD:64 AMD patients with Atrophy complication, mostly atrophic areas. Ophthalmologic exam included ETDRS visual acuity, complete ophthalmic examination, Fundus examination, Multimodal imaging:autofluorescence imaging (FAF), (Region Finder Software),optical coherence tomography (Spectralis HRA‐OCT),OCTen face, Morphology‐Structural software (M‐S).Cognitive evaluation is done for all of them with MMSE:Mini Mental State Examination (Folstein, GRECO),score allow to determine various groups, subgroups. Lipidomic Study:Blood tests and analysis, all lipids qualitative, quantitative analysis, all the same for 10 of those 64 patients. Blood test is done during ophthalmologic exam. Plasma congelation ‘snap frost’ after total blood centrifugation, then liquid‐liquid extraction for lipids analysis:neutral lipid, fatty acid, phospholipids, as sphingolipids, Polyinsatured fatty acids too Results MMSE:77% MCI cases (most moderate MCI (30.6%)),quite equal repartition in each score value, MCI subgroup (mild, moderate, intense, severe),quite same impairment in each MCI subgroup. Lipidomics:low levels for each and most of lipids, higher for Sphingosins (highest level),sphingosine1‐Phosphate, total neutral lipids, phospholipids total and PC (lowest levels).Results are effective, statistically significative. Multimodal imaging, M‐S:more and predominant drusenoids deposits Lipid type, ‘L’, presents, individualized, underlined. So, those results, parameters become and are Biomarkers for AMD Atrophy complication, allow better AMD follow‐up and etiopathogeny understanding Conclusions Each clinical, biological, multimodal entity, all, together or not, are Biomarkers, allow AMD screening, follow‐up, particularly AMD Atrophy complication. They also lead to better etiopathogeny understanding and therapeutics prospects.